What if tdap was given subcutaneously?

If the Tdap vaccine were given subcutaneously instead of intramuscularly, it could potentially lead to differences in the immune response and efficacy. Subcutaneous administration may result in reduced absorption and a lower concentration of the vaccine components in the bloodstream, possibly leading to a less robust immune response. Additionally, the safety profile and potential for local reactions could differ, necessitating further studies to evaluate the impact of such a change in administration route. Overall, maintaining the intramuscular route is essential for ensuring optimal vaccine effectiveness.